A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Conditions
- Ph+ ALL
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
- DRUG: Olverembatinib
- DRUG: Investigator's choice of TKI
Sponsor
Ascentage Pharma Group Inc.
Collaborators